Thrombin generation is thought to be mediated predominantly by the tissue factor or ''extrinsic'' coagulation pathway. An alternate pathway to thrombin generation (the ''intrinsic'' pathway or contact system) has been observed when blood or plasma comes in contact with artificial surfaces. Here we present evidence for a new route to thrombin formation that begins with the activation of the contact system protein prekallikrein by oversulfated heparin (OS-HB). Kallikrein, instead of activated factor X, cleaves prothrombin to form thrombin. Thrombin then cleaves fibrinogen to form fibrin clots. Moreover, we show that OS-HB by-products induce kallikrein-and thrombin-like activities in normal human plasma and in human plasma devoid of coagulation factor X or downstream contact system components factor IX or factor XI. Oversulfated heparin by-product-induced thrombin generation may have had a role in the adverse reactions associated with the recent clinical use of contaminated heparin.
Phospholipids Introduction
Glycosaminoglycans (GAGs) are linear polysaccharides comprised of repeating hexosamine-containing disaccharides. They are found covalently linked to surface proteins of most animal cells and also secreted into the extracellular space. Several GAG forms, including heparan sulfate, chondroitin sulfate, and dermatan sulfate, are sulfated to varying degrees at several sites on their distinctive disaccharide repeats. Heparin, a highly sulfated form of heparan sulfate, is an anticoagulant that has been used for the prevention and treatment of thromboembolic disorders for 70 years. In 2007 and 2008, hundreds of anaphylactic reactions and at least 149 deaths were associated with contaminated heparin. 1, 2 It was subsequently shown that the suspect heparin lots activate the contact system, which could cause the anaphylactic reactions observed in the affected patients. 3 The contact system initiates complement activation, 3 inflammation, 4 and other signaling pathways in blood circulation. 5 Activated kallikrein produces bradykinin from highmolecular-weight kininogen (HMWK), 5 whereas thrombin 6, 7 produces the anaphylatoxins C3a and C5a. Oversulfated chondroitin sulfate, found in the suspect lots, was shown to induce the formation of kallikrein, a key contact system component, and the generation of bradykinin, and C3a and C5a.
Recently we examined a panel of polyanionic molecules for their impact on the contact system. We observed that treatment of human plasma with several species of oversulfated GAGs, including an oversulfated heparin by-product (OS-HB), induced not only contact system activation (as indicated by the generation of kallikrein-like activity) but also thrombin-like activity. 8 Here we demonstrate that purified kallikrein can cleave prothrombin to form active thrombin, and we propose this reaction plays a role in thrombin generation in vivo.
The generation of thrombin from prothrombin is a critical step in blood coagulation. It is thought to be mediated predominantly by the tissue factor or ''extrinsic'' coagulation pathway, an enzyme cascade that leads to factor X (FX) activation. 9 The activated form of FXa cleaves prothrombin to form an active protease thrombin. An alternate pathway to thrombin (the ''intrinsic'' pathway or contact system) has been observed when blood or plasma comes in contact with artificial surfaces. 5 We present evidence that treatment of plasma with OS-HB or with cephalin plus silica (another contact system activator) induces the generation of thrombin in plasma devoid of coagulation FX or downstream contact system components factor IX (FIX) or factor XI (FXI). Direct cleavage of prothrombin by kallikrein could play a major role in the adverse reactions associated with the recent clinical use of contaminated heparin.
Materials and Methods

Materials
Heparin (H4784), kallikrein substrate, N-Benzoyl-Pro-Phe-Arg-p-nitroanilide hydrochloride, and thrombin substrate, Sar-Pro-Arg p-nitroanilide dihydrochloride, were purchased from Sigma (St. Louis, MO). Heparin by-product (HB) was provided by the Food and Drug Administration (FDA). It contained *50% heparin/heparan sulfate and *50% chondroitin/dermatan sulfate based on glucosamine/ galactosamine quantification, heparin lyase digestion, chondroitinase digestion, Capillary Electrophoresis (CE), nuclear magnetic resonance (NMR), and liquid chromatography/mass spectrometry (LC/ MS) analysis. 10 Oversulfated HB was chemically sulfated and analyzed using both CE and NMR in our laboratory as described. 8 All factor-depleted plasmas and antibodies used in this study were from Affinity Biologicals, Inc. (Ontario, Canada). The factordepleted plasmas included prothrombin-depleted, kallikrein-depleted, FXII-depleted, kininogendepleted, FIX-depleted, FX-depleted, FXI-depleted, antithrombin-depleted, and heparin cofactor IIdepleted. The antibodies included sheep antihuman thrombin, sheep anti-human prothrombin, goat anti-human FXII, sheep anti-human prekallikrein, sheep anti-human kininogen, sheep antihuman C1-inhibitor, and sheep anti-human TAFI. Control human plasma pooled from 30þ normal donors was purchased from George King Biomedical, Inc. (Overland Park, KS, USA). The pooled normal human plasma (0.5 mL Â 100 aliquots) was shipped on dry ice and stored atÀ70 C until use. We used pooled normal human plasmas form George King Biomedical, Inc for our experiments because the same plasmas are used at Barnes and Jewish Hospital in St Louis, Missouri, as standard control human plasmas for routine clinical coagulation tests. Human prothrombin-, prekallikrein-, and FXIIdeficient plasmas were also purchased from George King Biomedical, Inc. Cephalin/silica, a standard aPTT reagent, was purchased from diagnostic Stago.
Western Analysis
Prothrombin (0.2 mg), thrombin (0.2 mg), kallikrein (0.2 mg), 0.2 mg kallikrein þ 1 mg prothrombin in the presence or absence of 4 mg OS-HB in 10 mL Tris buffered saline (TBS) were incubated at 37 C for 5 minutes. After adding 10 mL sodium dodecyl sulfate (SDS) loading buffer, half of the sample (10 mL) was used for SDS polyacrylamide gel electrophoresis (SDS-PAGE) and then the gel was transferred onto a nitrocellulose membrane. After blotting with the primary and secondary antibodies, protein was visualized using the SuperSignal West Pico Chemiluminescent Substrate from Thermo-Scientific-Pierce (Waltham, MA, USA).
Kallikrein and Thrombin Activity Assays
Plasmas were treated in vitro by adding 20 mL of heparin, OS-HB, or cephalin/silica into 30 mL of plasma at 37 C for 5 minutes, with a final concentration of 0, 2, and 20 mg/mL for each in a 96-well plate. Tris buffered saline (50 mmol/L Tris pH 7.6, 50 mmol/L NaCl buffer) was then added to each well to a total volume of 150 mL. Absorbance at 405 nm was recorded as blank by Spectramax M2 plate reader (Molecular Devices, Silicon Valley, CA). Substrate (50 mL in TBS) was added to each well and absorbance at 405 nm was recorded every 90 seconds for 40 minutes. For the kallikrein and thrombin assays, 0.5 mmol/L N-Benzoyl-Pro-Phe-Arg-pnitroanilide hydrochloride and 1 mmol/L Sar-Pro-Arg p-nitroanilide dihydrochloride were used as substrates, respectively. Both substrates were dissolved in TBS buffer.
Fibrinogen Clotting Assay
The reaction mixture contained 1 mg/mL fibrinogen, 10 mmol/L CaCl 2 , 1 unit (0.33 mg) thrombin standard, or thrombin generated by kallikrein. Thrombin was generated by incubating 1 mg kallikrein with 5 mg prothrombin in 50 mL TBS containing 6% Bovine serum albumin (BSA) at 37 C for 5 minutes, 1 hour, or 2 hours. The clotting time was measured using a fibrometer (GSR Technical Sales, Inc; Alberta, Canada).
Results
Induction of Thrombin Activity From Prothrombin by Kallikrein
Although activation of the contact system is known to produce thrombin, the process is thought to proceed primarily via an enzyme cascade that leads to FX activation. It is FXa that cleaves prothrombin to form an active protease. 9 Recently Steif showed that incubating purified prothrombin with kallikrein can produce a protease activity that cleaves Sar-Pro-Arg-p-nitroanilide, a thrombin substrate. 11 Thus, it is possible that kallikrein may activate prothrombin directly. We used several approaches to examine this possibility further:
1. We incubated 0.5 mg/mL kallikrein, 5 mg/mL prothrombin, and 0.2 mmol/L of the thrombin substrate (Sar-Pro-Arg p-nitroanilide) in TBS buffer. Thrombin activity was determined by increased optical density (OD) at 405 nm due to its chromogenic substrate cleavage ( Figure 1A ). As reported by Stief, 11 prothrombin and kallikrein incubated together produced an activity that could cleave the thrombin-specific chromogenic substrate. 11 Further analysis indicated that approximately 80% of that production of that activity was inhibited by hirudin, a thrombin-specific inhibitor ( Figure 1A ). No activity was obtained when the substrate was incubated with prothrombin alone. 2. We examined the effects of kallikrein on the prothrombin protein. We incubated kallikrein and prothrombin at 37 C for 5 minutes (as above), fractionated the reaction products by SDS-PAGE, and performed a Western blot analysis with antithrombin antibody ( Figure 1B ). Incubation of prothrombin with kallikrein resulted in thrombin protein that matched the thrombin standard ( Figure 1B, lanes 2 and 4) and, in addition, produced a protein by its size likely to be meizothrombin (desF1), an intermediate in the generation of thrombin from prothrombin ( Figure 1B,  lane 4) . Adding OS-HB to kallikrein and prothrombin did not appear to influence the amount of thrombin or meizothrombin (desF1) generated ( Figure 1B, lanes 4 and 5) . 3. We examined the capacity of the thrombin activity, generated by kallikrein from prothrombin, to direct fibrinogen clotting. To that end 1 mg of kallikrein and 5 mg of prothrombin were preincubated together (as above) for 5 minutes, 1 hour, or 2 hours. Samples of these reaction mixtures were then incubated in 1 mg/mL fibrinogen solution for up to 500 seconds. Samples from reactions pre-incubated for the full 2 hour resulted in clotting times of 18.6 + 0.8 seconds, similar to the clotting time produced by the thrombin standard (0.33 mg; 16.3 + 0.4 seconds). Shorter pre-incubation times (5 minutes, 1 hour) led to longer clotting times (>100, 41.2 + 6 seconds, respectively). In contrast, no clotting was observed (>500 seconds) with 1 or 10 mg kallikrein pre-incubated alone for up to 2 hours.
Oversulfated HB, Heparin, and Cephalin (phosphatidylethanolamine/silica) Induction of Thrombin-and Kallikrein-Like Activities in Human Plasmas
In a concurrent study, we showed that a variety of oversulfated GAGs including OS-HB introduced to human plasma can induce kallikrein activity. 8 In addition, we observed increases in thrombin activity that paralleled to that of kallikrein. Given that purified kallikrein can activate thrombin (above), we asked whether this reaction might occur in a more physiological environment. Therefore, we incubated OS-HB in a variety of normal and factor-depleted human plasmas and measured the resulting changes in thrombin-and kallikrein-like activity (Figure 2 ). We used heparin as a negative control because we had previously observed minimal effects of heparin on kallikrein or thrombin-like activity. 8 In addition, we used cephalin plus silica as a positive control because this is a clinical clotting reagent that induces thrombin through contact system activation. 5 Oversulfated HB treatment induced both thrombin-like and kallikrein-like activity in normal human plasma (Figure 2) . Maximum thrombin activity and near-maximum kallikrein activity were detected at 2 mg/mL activator. Under those conditions the induction of both thrombin-like and kallikrein-like activities was dependent on the presence of plasma pre-kallikrein. Moreover, thrombinlike activity but not kallikrein-like activity required the presence of kininogen, the upstream contact system component. Interestingly, the activity was dependent neither on the downstream contact system components factor IX and factor XI nor on the factor X, a component common to both the contact system and the tissue factor (extrinsic) coagulation pathways.
Cephalin plus silica treatment also induced both thrombin-like and kallikrein-like activity in control plasma (Figure 2 ). In this case, maximum thrombin and kallikrein activities were detected at 20 mg/mL of activator. Under those conditions, the induction of both thrombin-like and kallikrein-like activities was, like the case of OS-HB activator, dependent on the presence of plasma prekallikrein. Both thrombin-like and kallikrein-like activities were dependent on the presence of kininogen, and, as with OS-HB, independent of FIX, FX, and FXI. Of note, maximum thrombin-and kallikrein-like activities were observed in the absence of C1-inh, the natural inhibitor of these and other plasma serine proteases, even in the absence of an inducer (Figure 2A and B) .
As expected, of the 3 potential activators, heparin had the least effect. Induction of thrombin-like activity was relatively modest at 20 mg/mL (Figure 2A) , whereas activation of kallikrein-like activity, albeit also modest, was difficult to interpret due to a relatively high background in the prekallikrein-depleted plasma ( Figure 2B ).
Discussion
It has been well established that in vivo blood coagulation is initiated by exposure of tissue factor that forms a complex with FVIIa, which results in the generation of small quantities of FIXa and FXa. FXa then generates minute amounts of thrombin that result in the activation of FVIII and FV. At this point, the FVIIIa, FIXa, and phospholipid (PL) form a ''tenase'' complex. The ''tenase'' generates sufficient quantities of FXa to form a ''prothrombinase'' complex, composed of FVa, FXa, Ca 2þ , and PL. The prothrombinase then generates sufficient thrombin to induce clot formation 12, 13 (Figure 3) .
In addition to the tissue factor or extrinsic pathway, an alternate pathway to thrombin generation (the intrinsic pathway or contact system) has been described when blood or plasma comes in contact with negatively charged artificial surfaces. 14 The physiological role of the contact system in thrombin generation has been largely dismissed during the past 50 years for 2 reasons: (1) Artificial surfaces that are required for contact system activation are not present in the blood; and (2) Genetic deficiencies in contact system proteins, such as factor XII or kininogen, are not associated with bleeding phenotypes. Nevertheless, with the advent of new therapeutic materials, the contact system may be of clinical importance.
Here we present evidence for a new route to thrombin formation that begins with the activation of the contact system component kallikrein and leads directly to the cleavage of prothrombin. We showed that purified kallikrein cleaves prothrombin to form an active enzyme that has fibrinogen-dependent clotting activity. Moreover, following our previous observation that treatment of plasma with oversulfated GAGs can induce kallikrein and thrombin activity, we showed that induction of kallikrein, and, most importantly, thrombin occurred in plasma devoid of intrinsic pathway components (FIX and FXI) and 1 component common to both the intrinsic and extrinsic pathways (FX; Figure 3 ). In addition, we demonstrated that kallikrein and thrombin activities could also be induced by cephalin plus silica, again independently of factors IX, X, and XI. Kininogen, an upstream component of the contact system, was required for kallikrein activity as induced by Cephalin plus silica but not by OS-HB, observations suggesting that OS-HB activates kallikrein by a novel mechanism. Incubation of OS-HB with purified kallikrein did not affect the capacity of kallikrein to cleave prothrombin (Figure 1, Lanes 5 ). By the simplest interpretation of our results, we propose that OS-HB (and other oversulfated GAGs) promote kininogen-independent cleavage of prekallikrein to form kallikrein, and kallikrein mediates thrombin formation via direct cleavage of prothrombin and by initiation of the intrinsic pathway enzyme cascade. Although we are aware of only 1 report that indicates that kallikrein might induce thrombin formation directly, Asmis et al 15 showed that clotting occurs in kaolin-treated FXII-depleted plasma in the absence of detectable FXI activation, suggesting the existence of a FXI-independent pathway.
Thromboembolic disorders are the leading cause of disabilities and death in a variety of unrelated human diseases, such as coronary heart disease, 16 cancer, 17 diabetes, 18 kidney failure, 19 autoimmune diseases, 20 and heparin-induced thrombocytopenia and thrombosis (HITT). 21 Thrombin is the only known enzyme that causes thrombus formation. However, thrombin also plays multiple roles in development, tissue repair, inflammation, and hemostasis. 9 Conditional loss of prothrombin leads to rapid deaths of adult mice, 22 suggesting that thrombin is a key survival factor which is continuously generated in blood circulation. Thus, it is critical to reexamine the role of kallikrein and the contact system in thrombin generation in vivo and abnormal thrombin generation in human thromboembolic disorders.
